CFTR and cystic fibrosis: We also found that the only clinically approved CFTR potentiator, VX770/Ivacaftor, did not rescue this loss of channel activity in clinically relevant primary airway epithelial cells both from non‐CF and CF donors (Stauffer et al., 2017).